Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | OMER |
---|---|---|
09:32 ET | 10480 | 3.84 |
09:34 ET | 4203 | 3.9 |
09:39 ET | 540 | 3.84 |
09:41 ET | 2600 | 3.8207 |
09:50 ET | 200 | 3.82 |
09:52 ET | 1454 | 3.81 |
09:56 ET | 7786 | 3.85 |
09:57 ET | 100 | 3.86 |
10:01 ET | 1300 | 3.86 |
10:03 ET | 200 | 3.86 |
10:06 ET | 200 | 3.85 |
10:10 ET | 500 | 3.84 |
10:12 ET | 631 | 3.81 |
10:14 ET | 2799 | 3.81 |
10:15 ET | 2500 | 3.83 |
10:17 ET | 100 | 3.83 |
10:24 ET | 200 | 3.835 |
10:26 ET | 100 | 3.82 |
10:28 ET | 500 | 3.83 |
10:35 ET | 1100 | 3.83 |
10:39 ET | 300 | 3.84 |
10:42 ET | 200 | 3.84 |
10:44 ET | 1600 | 3.81 |
10:46 ET | 600 | 3.81 |
10:48 ET | 500 | 3.82 |
10:50 ET | 100 | 3.82 |
10:51 ET | 100 | 3.84 |
10:55 ET | 370 | 3.84 |
11:00 ET | 100 | 3.85 |
11:02 ET | 264 | 3.85 |
11:04 ET | 900 | 3.87 |
11:08 ET | 470 | 3.86 |
11:09 ET | 500 | 3.86 |
11:15 ET | 500 | 3.86 |
11:22 ET | 100 | 3.84 |
11:24 ET | 1997 | 3.79 |
11:26 ET | 200 | 3.795 |
11:27 ET | 100 | 3.795 |
11:29 ET | 100 | 3.79 |
11:31 ET | 900 | 3.785 |
11:33 ET | 1464 | 3.8 |
11:36 ET | 705 | 3.78 |
11:38 ET | 100 | 3.785 |
11:40 ET | 100 | 3.785 |
11:42 ET | 2035 | 3.8 |
11:44 ET | 1729 | 3.8 |
11:45 ET | 100 | 3.795 |
11:49 ET | 100 | 3.795 |
11:51 ET | 800 | 3.79 |
11:54 ET | 500 | 3.7864 |
11:56 ET | 1200 | 3.79 |
11:58 ET | 310 | 3.79 |
12:02 ET | 200 | 3.795 |
12:03 ET | 200 | 3.79 |
12:12 ET | 1300 | 3.8 |
12:14 ET | 1218 | 3.815 |
12:18 ET | 700 | 3.825 |
12:25 ET | 1000 | 3.825 |
12:27 ET | 200 | 3.82 |
12:32 ET | 100 | 3.825 |
12:34 ET | 700 | 3.81 |
12:38 ET | 565 | 3.81 |
12:39 ET | 100 | 3.81 |
12:41 ET | 600 | 3.83 |
12:43 ET | 500 | 3.82 |
12:45 ET | 200 | 3.82 |
12:50 ET | 200 | 3.825 |
12:52 ET | 700 | 3.82 |
12:54 ET | 1800 | 3.79 |
12:56 ET | 227 | 3.7909 |
12:59 ET | 100 | 3.795 |
01:01 ET | 1100 | 3.79 |
01:03 ET | 100 | 3.785 |
01:06 ET | 200 | 3.78 |
01:10 ET | 2450 | 3.795 |
01:12 ET | 300 | 3.79 |
01:14 ET | 100 | 3.79 |
01:15 ET | 1100 | 3.79 |
01:17 ET | 100 | 3.79 |
01:19 ET | 600 | 3.795 |
01:24 ET | 300 | 3.785 |
01:28 ET | 1000 | 3.7893 |
01:32 ET | 4875 | 3.765 |
01:33 ET | 1298 | 3.765 |
01:35 ET | 995 | 3.78 |
01:39 ET | 680 | 3.77 |
01:42 ET | 100 | 3.77 |
01:46 ET | 100 | 3.775 |
01:48 ET | 100 | 3.775 |
01:50 ET | 100 | 3.775 |
01:51 ET | 200 | 3.77 |
01:53 ET | 300 | 3.7699 |
01:55 ET | 1200 | 3.77 |
01:57 ET | 300 | 3.775 |
02:02 ET | 1351 | 3.765 |
02:06 ET | 500 | 3.765 |
02:08 ET | 600 | 3.7609 |
02:09 ET | 1292 | 3.77 |
02:11 ET | 500 | 3.785 |
02:15 ET | 1100 | 3.8 |
02:18 ET | 100 | 3.8 |
02:22 ET | 100 | 3.8 |
02:24 ET | 200 | 3.8 |
02:27 ET | 1200 | 3.82 |
02:29 ET | 200 | 3.815 |
02:33 ET | 1559 | 3.805 |
02:36 ET | 200 | 3.8 |
02:38 ET | 200 | 3.8 |
02:40 ET | 100 | 3.8 |
02:44 ET | 3300 | 3.785 |
02:45 ET | 1500 | 3.77 |
02:47 ET | 400 | 3.765 |
02:49 ET | 100 | 3.765 |
02:54 ET | 1400 | 3.77 |
03:00 ET | 1000 | 3.775 |
03:03 ET | 100 | 3.775 |
03:05 ET | 100 | 3.775 |
03:07 ET | 2000 | 3.8 |
03:14 ET | 733 | 3.79 |
03:16 ET | 600 | 3.79 |
03:23 ET | 1000 | 3.81 |
03:25 ET | 100 | 3.82 |
03:27 ET | 200 | 3.81 |
03:30 ET | 100 | 3.8 |
03:32 ET | 2233 | 3.79 |
03:34 ET | 2467 | 3.77 |
03:36 ET | 1000 | 3.775 |
03:38 ET | 1400 | 3.765 |
03:39 ET | 3895 | 3.76 |
03:41 ET | 2500 | 3.765 |
03:43 ET | 9510 | 3.78 |
03:45 ET | 400 | 3.78 |
03:48 ET | 8395 | 3.76 |
03:50 ET | 4196 | 3.775 |
03:52 ET | 2689 | 3.76 |
03:54 ET | 2100 | 3.75 |
03:56 ET | 10403 | 3.755 |
03:57 ET | 7124 | 3.775 |
03:59 ET | 42721 | 3.77 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Omeros Corp | 219.6M | -1.1x | --- |
Trevi Therapeutics Inc | 219.2M | -7.8x | --- |
Candel Therapeutics Inc | 215.3M | -3.9x | --- |
XBiotech Inc | 214.8M | -6.5x | --- |
Acrivon Therapeutics Inc | 213.4M | -2.5x | --- |
Immutep Ltd | 310.4M | -8.5x | --- |
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in a phase I multi-ascending-dose clinical trial. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. The Company’s lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $218.5M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.48 |
EPS | $-3.32 |
Book Value | $-0.41 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.